41 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
15 Jun 24
, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
13 Jun 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
® (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
5 Jun 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
5p44no2v rkmkkksa9xjj5dt13jyvmzqiqjitb
FGEN
REGN
4 Jun 24
Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new
q2es4f1enoynmxq0sr
REGN
3 Jun 24
New York, New York--(Newsfile Corp. - June 3, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals
0o74czhhm5
FGEN
REGN
3 Jun 24
in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also
dli x2ghleunp
REGN
SNY
31 May 24
Investigational Drug Shows Potential.
Price Action: SNY shares were trading higher by 0.63% at $48.13 premarket at the last check on Friday.
Photo by HJBC via Shutterstock
0sb7h0px25agfg x9fr3bf589p3ip7d
REGN
31 May 24
. The use of Dupixent in COPD is investigational and is not yet approved by global regulatory authorities. About
lbiro8a31jfnceq1du1sj5km3bsnxn pqpucb
REGN
31 May 24
is September 27, 2024. The use of Dupixent in COPD is investigational and is not yet approved by global regulatory authorities
868qxt6y7cfi1ig6
REGN
31 May 24
play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab. Dupixent
vetwjtbzn43jpwavgn6nxuvk2td1gtyj4agjwatq2njqnpvbwm aad3qew
REGN
31 May 24
different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent
e50tbtmf83chuufrwj3pf6w9rxg t9diakeep5jp0lxop5jw2zorn3i8rct
REGN
30 May 24
, May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
pvbn4r 3tvit8x
BHVN
REGN
29 May 24
on investigating a new drug. Biohaven anticipates to have Myostatin program data for Phase 3 spinal muscular atrophy in the second half of 2024.
Related
8uyhyf6cv00nwfrf
REGN
28 May 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
5qyvzf fg2bv8kxycqe6xq89bqn67k1wu6asle4jbfhqmr8p6l
ABBV
ACAD
BAYRY
24 May 24
Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation.
Price Action
itxni0juucvd1iion9dsljaciq9dic53fcg2hi7y2rsrjl98 byd61
REGN
23 May 24
historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially
wrmpprk3uezl 4i72gxt6k4htyw47r
REGN
22 May 24
, May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
zyprcywrh1 eiyebrpgc1za71oszvplc0i6pomys
REGN
20 May 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company